Molecular profiling company Caris Life Sciences and AI-powered data solutions provider ConcertAI have announced an extension to their original partnership (which was initially announced in January 2023) to create a clinico-genomic platform.
The partnership aims to generate a comprehensive database of molecular and clinical data that will provide insights for precision medicine, therapeutic development, and clinical trial management. The initiative will enable multi-year programs focused on specific cancers and molecular targets, supporting translational sciences, clinical development, and post-approval evidence generation leveraging ConcertAI's clinical data and Caris' molecular profiling capabilities.
The partnership involves aligning clinical trial networks, patient identification and matching solutions, scientific talent, and AI technologies. The initiative will facilitate access to large-scale, integrated data and technologies, accelerating research, and benefiting cancer patients with limited therapeutic options by providing access to comprehensive and extensive data for improved patient care.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.